

# Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	5	6.5	76.7	(24.7-179.1)	Female	1	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	2.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	4	1.7	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	3	7.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.2	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.6	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	17	24.0	70.9	(41.3-113.5)
Male	1	0.6	nc	(nc-nc)	Female	21	21.4	98.3	(60.8-150.3)
Female	1	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	3.0	nc	(nc-nc)					
Female	1	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	6.9	86.9	(31.7-189.1)	Male	5	4.9	103.1	(33.2-240.6)
Female	0	2.0	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	25	25.8	96.9	(62.7-143.0)	Female	2	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	8.3	84.3	(33.8-173.8)	Female	2	2.3	nc	(nc-nc)
Female	6	6.6	90.2	(33.0-196.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	2.3	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	20	26.4	75.9	(46.3-117.2)
Male	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.8	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	8	5.6	142.4	(61.3-280.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.8	nc	(nc-nc)	Female	7	5.7	122.0	(48.9-251.4)
Female	0	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	73	96.7	75.5	(59.2-95.0)
Male	1	2.2	nc	(nc-nc)	Female	76	83.8	90.7	(71.5-113.6)
Female	0	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	11	12.6	87.1	(43.4-155.9)					
Female	8	10.6	75.4	(32.4-148.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	49	39.3	124.6	(92.1-164.7)	Male	21	26.3	79.9	(49.4-122.1)
Female	22	16.4	134.5	(84.2-203.6)	Female	21	24.5	85.7	(53.0-131.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	7.9	101.1	(43.5-199.2)	Male	2	6.8	nc	(nc-nc)
Female	5	7.6	65.7	(21.2-153.2)	Female	4	6.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	35	23.2	150.9	(105.1-209.9)
Female	200	170.4	117.4	(101.6-134.8)	Female	23	21.8	105.6	(66.9-158.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	6.6	90.4	(33.0-196.8)	Male	19	16.6	114.6	(69.0-178.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	48	46.3	103.8	(76.5-137.6)	Female	14	15.9	88.3	(48.2-148.1)
Female	56	53.8	104.0	(78.6-135.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	15	10.5	143.1	(80.1-236.1)	Male	14	12.8	109.8	(60.0-184.2)
Female	3	3.4	nc	(nc-nc)	Female	19	16.2	117.6	(70.7-183.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	13	9.3	140.4	(74.7-240.1)
Female	6	3.5	171.6	(62.7-373.6)	Female	6	6.5	92.9	(33.9-202.2)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	30	21.2	141.4	(95.3-201.8)	Male	4	6.3	nc	(nc-nc)
Female	15	14.1	106.3	(59.4-175.3)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	6.0	132.6	(57.1-261.3)	Female	41	39.0	105.1	(75.4-142.6)
Female	4	2.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	20	15.2	131.6	(80.4-203.3)	Male	605	535.6	113.0	(104.1-122.3)
Female	11	12.9	85.1	(42.4-152.3)	Female	623	599.4	103.9	(95.9-112.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	12	12.1	99.3	(51.3-173.6)					
Female	4	4.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	84	70.8	118.7	(94.7-147.0)					
Female	74	84.5	87.5	(68.7-109.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	9.5	158.3	(88.5-261.1)	Male	11	6.6	167.2	(83.4-299.2)
Female	3	3.2	nc	(nc-nc)	Female	3	4.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	6	5.7	105.9	(38.7-230.6)
Female	45	36.6	122.9	(89.7-164.5)	Female	9	4.4	206.6	(94.3-392.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.4	nc	(nc-nc)	Male	5	4.4	112.8	(36.3-263.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	13	11.5	113.4	(60.3-194.0)	Female	4	3.3	nc	(nc-nc)
Female	13	10.3	126.4	(67.2-216.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	32	40.8	78.4	(53.6-110.7)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	5.6	143.1	(61.6-282.0)	Female	11	8.6	127.4	(63.5-228.0)
Female	2	2.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	3.3	nc	(nc-nc)	Male	16	18.2	88.0	(50.3-143.0)
Female	2	1.0	nc	(nc-nc)	Female	30	17.4	172.3	(116.2-246.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	4.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	1.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	5.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
					Male	9	17.4	51.6	(23.6-98.0)
					Female	8	13.4	59.7	(25.7-117.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	21.3	94.0	(57.4-145.3)	Male	24	14.5	165.0	(105.7-245.5)
Female	9	8.6	104.8	(47.8-198.9)	Female	21	12.4	169.5	(104.9-259.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	4.3	161.5	(64.7-332.8)	Male	6	3.8	155.9	(56.9-339.3)
Female	8	3.9	206.0	(88.7-405.9)	Female	2	3.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	15	12.8	117.0	(65.4-193.0)
Female	99	92.1	107.5	(87.4-130.9)	Female	14	11.4	122.8	(67.1-206.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.4	nc	(nc-nc)	Male	10	9.8	102.1	(48.9-187.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	26	25.9	100.4	(65.6-147.1)	Female	10	8.4	119.3	(57.1-219.4)
Female	24	28.1	85.5	(54.8-127.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	7.1	113.1	(48.7-222.8)
Male	5	6.0	83.1	(26.8-194.0)	Female	7	8.4	82.8	(33.2-170.7)
Female	0	1.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	133	87.9	151.2	(126.6-179.2)
Male	4	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	3.3	nc	(nc-nc)
Male	13	12.3	106.0	(56.4-181.3)	<b><u>Testis</u></b>				
Female	10	7.5	133.2	(63.8-245.0)	Male	3	2.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	5	5.1	97.6	(31.5-227.8)
Female	1	1.1	nc	(nc-nc)	Female	13	16.3	79.7	(42.4-136.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	15	8.2	182.8	(102.2-301.5)	Female	19	21.1	90.0	(54.2-140.6)
Female	5	6.7	75.1	(24.2-175.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	368	301.5	122.1	(109.9-135.2)
Male	5	7.2	69.6	(22.4-162.5)	Female	325	316.2	102.8	(91.9-114.6)
Female	3	2.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	27	39.7	68.1	(44.9-99.1)					
Female	41	45.1	91.0	(65.3-123.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	44	30.7	143.1	(104.0-192.1)	Male	13	20.4	63.8	(33.9-109.0)
Female	9	12.9	69.8	(31.9-132.5)	Female	14	17.7	79.3	(43.3-133.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	5.9	nc	(nc-nc)	Male	7	5.4	129.7	(52.0-267.3)
Female	12	5.5	219.2	(113.2-383.0)	Female	2	4.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	18	17.6	102.0	(60.4-161.2)
Female	142	130.3	109.0	(91.8-128.5)	Female	16	16.8	95.5	(54.5-155.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.6	nc	(nc-nc)	Male	15	13.0	115.4	(64.5-190.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	43	35.7	120.5	(87.2-162.3)	Female	9	12.0	74.8	(34.1-142.0)
Female	43	41.6	103.3	(74.8-139.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	10.1	79.2	(34.1-156.0)
Male	9	8.4	107.4	(49.0-203.9)	Female	18	12.7	141.6	(83.9-223.8)
Female	3	2.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	117	121.8	96.1	(79.5-115.1)
Male	4	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	10	7.1	140.1	(67.1-257.7)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	5.0	nc	(nc-nc)
Male	27	16.7	161.8	(106.6-235.4)	<b><u>Testis</u></b>				
Female	12	10.9	109.8	(56.7-191.8)	Male	10	3.9	258.9	(124.0-476.2)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	7	4.8	145.1	(58.1-299.1)	Male	10	6.9	145.0	(69.4-266.7)
Female	3	1.6	nc	(nc-nc)	Female	16	22.2	72.1	(41.2-117.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	14	11.3	123.4	(67.4-207.0)	Female	25	30.3	82.4	(53.3-121.7)
Female	7	9.6	72.8	(29.2-149.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	465	420.7	110.5	(100.7-121.0)
Male	7	9.7	72.4	(29.0-149.1)	Female	463	457.8	101.1	(92.1-110.8)
Female	0	3.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	66	56.9	115.9	(89.7-147.5)					
Female	76	67.6	112.4	(88.6-140.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Male</u></b>				
Male	0	0.2	nc	(nc-nc)	Obs	10	14.8	67.7	(32.4-124.5)
Female	0	0.0	nc	(nc-nc)	<b><u>Female</u></b>				
<b><u>Leukemia</u></b>					Obs				
Male	0	0.4	nc	(nc-nc)	Exp	9.5	nc	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>SIR</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					67.7				
Male	0	0.4	nc	(nc-nc)	<b><u>95% CI</u></b>				
Female	0	0.1	nc	(nc-nc)	(32.4-124.5)				
<b><u>Lung and Bronchus</u></b>					<b><u>nc</u></b>				
Male	2	2.0	nc	(nc-nc)	nc				
Female	0	1.3	nc	(nc-nc)	nc				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	21.3	126.5	(83.3-184.0)	Male	38	13.6	279.3	(197.6-383.3)
Female	7	8.2	85.6	(34.3-176.4)	Female	25	11.5	218.0	(141.1-321.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.9	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	4	3.6	nc	(nc-nc)	Female	7	3.2	222.1	(89.0-457.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	16	12.0	133.7	(76.4-217.1)
Female	106	86.7	122.2	(100.1-147.8)	Female	10	10.8	92.8	(44.4-170.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.1	nc	(nc-nc)	Male	17	8.6	197.0	(114.7-315.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	25	24.6	101.6	(65.7-150.0)	Female	6	7.9	75.9	(27.7-165.2)
Female	24	26.6	90.4	(57.9-134.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	6.9	nc	(nc-nc)
Male	4	5.7	nc	(nc-nc)	Female	11	8.0	136.7	(68.2-244.7)
Female	0	1.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	80	81.3	98.4	(78.0-122.4)
Male	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	4	1.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	3.2	nc	(nc-nc)
Male	6	11.1	53.8	(19.7-117.2)	<b><u>Testis</u></b>				
Female	7	7.1	98.2	(39.4-202.4)	Male	4	2.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	3.2	nc	(nc-nc)	Male	5	4.4	112.6	(36.3-262.8)
Female	1	1.1	nc	(nc-nc)	Female	16	14.7	108.6	(62.1-176.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	12	8.0	150.6	(77.7-263.1)	Female	18	20.1	89.5	(53.0-141.5)
Female	10	6.2	160.2	(76.7-294.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	315	284.4	110.8	(98.9-123.7)
Male	3	6.4	nc	(nc-nc)	Female	340	298.2	114.0	(102.2-126.8)
Female	1	2.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	31	38.6	80.2	(54.5-113.9)					
Female	59	43.3	136.4	(103.8-175.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	16.0	93.9	(52.5-154.9)	Male	13	10.4	125.0	(66.5-213.7)
Female	2	5.2	nc	(nc-nc)	Female	3	8.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.0	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	7	9.2	76.0	(30.5-156.7)
Female	57	59.4	96.0	(72.7-124.4)	Female	6	7.1	84.4	(30.8-183.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.2	nc	(nc-nc)	Male	5	6.7	75.1	(24.2-175.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	16	18.8	85.2	(48.7-138.4)	Female	5	5.3	93.6	(30.2-218.4)
Female	17	17.1	99.2	(57.8-158.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	5.2	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	Female	5	5.1	97.5	(31.4-227.6)
Female	1	1.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	48	61.6	77.9	(57.4-103.3)
Male	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	2.0	nc	(nc-nc)
Male	7	8.7	80.6	(32.3-166.1)	<b><u>Testis</u></b>				
Female	3	4.8	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	5	3.5	143.2	(46.2-334.3)
Female	0	0.7	nc	(nc-nc)	Female	10	11.0	91.0	(43.6-167.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	5.9	nc	(nc-nc)	Female	8	13.6	58.7	(25.3-115.7)
Female	5	4.1	121.6	(39.2-283.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	172	216.3	79.5	(68.1-92.3)
Male	1	4.9	nc	(nc-nc)	Female	169	200.1	84.5	(72.2-98.2)
Female	0	1.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	18	29.7	60.5	(35.8-95.6)					
Female	21	28.0	74.9	(46.4-114.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	18.6	96.5	(57.2-152.6)	Male	14	12.8	109.3	(59.7-183.3)
Female	5	6.0	82.7	(26.6-193.0)	Female	12	9.7	124.2	(64.1-217.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.9	nc	(nc-nc)	Male	5	3.4	147.1	(47.4-343.3)
Female	3	3.0	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.6	nc	(nc-nc)	Male	20	11.2	177.8	(108.6-274.6)
Female	79	72.8	108.6	(86.0-135.3)	Female	8	8.4	95.5	(41.1-188.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.8	nc	(nc-nc)	Male	5	8.7	57.6	(18.6-134.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	21	23.0	91.5	(56.6-139.8)	Female	8	6.5	123.8	(53.3-243.9)
Female	20	20.1	99.6	(60.8-153.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	6.3	143.7	(65.6-272.8)
Male	6	5.3	113.1	(41.3-246.2)	Female	8	5.9	135.2	(58.2-266.5)
Female	0	1.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	76	78.3	97.1	(76.5-121.5)
Male	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	2.3	nc	(nc-nc)
Male	8	10.9	73.5	(31.7-144.9)	<b><u>Testis</u></b>				
Female	9	5.7	158.7	(72.4-301.3)	Male	4	2.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	3.1	nc	(nc-nc)	Male	5	4.6	109.7	(35.4-256.1)
Female	1	0.9	nc	(nc-nc)	Female	26	13.6	190.8	(124.6-279.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	7.3	nc	(nc-nc)	Female	15	16.6	90.3	(50.5-149.0)
Female	4	4.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	254	266.7	95.3	(83.9-107.7)
Male	1	6.3	nc	(nc-nc)	Female	253	239.5	105.6	(93.0-119.5)
Female	1	1.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	22	34.8	63.2	(39.6-95.6)					
Female	28	32.3	86.7	(57.6-125.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	4.9	143.4	(57.5-295.5)	Male	3	3.2	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	5	2.1	233.8	(75.3-545.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	23	16.1	142.6	(90.4-213.9)	Female	1	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	5.8	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	2	5.0	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	1.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	14	20.8	67.2	(36.7-112.7)
Male	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.6	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.7	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	47	68.3	68.9	(50.6-91.6)
Male	1	1.6	nc	(nc-nc)	Female	56	55.8	100.3	(75.8-130.3)
Female	1	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	9.3	64.8	(23.7-141.0)					
Female	11	8.2	133.5	(66.6-238.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	5	1.9	269.8	(86.9-629.6)
Female	0	1.1	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	11	10.5	105.2	(52.5-188.3)	Female	3	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	3.6	165.3	(60.4-359.8)	Female	1	1.0	nc	(nc-nc)
Female	6	3.7	163.1	(59.6-355.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	1	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	13	10.8	119.9	(63.8-205.0)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	1	1.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	1.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	5	2.4	206.0	(66.4-480.7)
Female	0	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	5	5.4	93.2	(30.0-217.5)	Male	42	39.4	106.6	(76.9-144.2)
Female	4	5.5	nc	(nc-nc)	Female	43	37.6	114.3	(82.7-154.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	4.8	nc	(nc-nc)	Male	6	3.1	191.9	(70.1-417.6)
Female	0	1.4	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	0.9	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	13	18.0	72.2	(38.4-123.5)	Female	0	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	5.6	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	0	4.8	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	1.6	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	20	19.4	103.3	(63.0-159.5)
Male	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.6	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	5	3.3	153.4	(49.4-357.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	1.9	nc	(nc-nc)	Female	5	4.2	120.2	(38.7-280.5)
Female	0	1.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	59	66.1	89.3	(67.9-115.1)
Male	1	1.5	nc	(nc-nc)	Female	49	58.3	84.0	(62.1-111.0)
Female	0	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	1	8.8	nc	(nc-nc)					
Female	7	7.9	88.7	(35.5-182.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	6.6	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	19	23.5	80.8	(48.6-126.2)	Female	0	2.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	8	8.4	94.8	(40.8-186.8)	Female	0	2.1	nc	(nc-nc)
Female	11	6.5	168.6	(84.0-301.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	1	1.8	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	1	0.9	nc	(nc-nc)	Female	29	25.7	113.0	(75.6-162.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	7	4.1	168.7	(67.6-347.6)	Female	2	1.7	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	2	1.1	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	2	2.8	nc	(nc-nc)	Female	5	4.6	108.0	(34.8-252.0)
Female	1	1.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	3	2.2	nc	(nc-nc)	Male	8	5.3	149.8	(64.5-295.3)
Female	0	0.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	24	12.1	198.8	(127.3-295.8)	Female	105	96.9	108.4	(88.6-131.2)
Female	15	10.6	141.1	(78.9-232.8)	Female	79	78.3	100.9	(79.9-125.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	36	30.5	117.8	(82.5-163.1)	Male	21	20.7	101.3	(62.7-154.8)
Female	14	12.9	108.5	(59.3-182.1)	Female	20	19.3	103.5	(63.2-159.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	6.5	185.1	(95.5-323.4)	Male	7	5.3	132.9	(53.2-273.8)
Female	4	6.1	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	33	18.6	177.9	(122.4-249.8)
Female	139	137.9	100.8	(84.7-119.0)	Female	14	17.2	81.2	(44.4-136.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	5.4	nc	(nc-nc)	Male	11	13.1	83.9	(41.8-150.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	36	36.6	98.3	(68.9-136.2)	Female	15	12.6	119.0	(66.6-196.3)
Female	43	42.9	100.2	(72.5-135.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	14	9.9	141.0	(77.0-236.5)
Male	14	8.0	174.2	(95.1-292.2)	Female	9	12.7	70.6	(32.2-134.1)
Female	1	2.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	125	112.8	110.8	(92.2-132.0)
Male	2	2.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	6	2.5	236.2	(86.2-514.1)	Male	5	7.3	68.6	(22.1-160.2)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	5.2	nc	(nc-nc)
Male	27	17.1	158.2	(104.2-230.1)	<b><u>Testis</u></b>				
Female	10	11.2	89.0	(42.6-163.8)	Male	10	4.9	204.8	(98.0-376.6)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	4.7	nc	(nc-nc)	Male	9	7.5	119.5	(54.5-226.9)
Female	1	1.6	nc	(nc-nc)	Female	15	26.4	56.8	(31.8-93.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	13	12.1	107.2	(57.0-183.4)	Female	32	30.8	103.9	(71.1-146.7)
Female	6	10.4	57.9	(21.1-126.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	486	416.6	116.7	(106.5-127.5)
Male	5	9.3	53.5	(17.2-124.9)	Female	414	477.8	86.6	(78.5-95.4)
Female	0	3.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	60	55.2	108.8	(83.0-140.0)					
Female	50	66.4	75.3	(55.9-99.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	6	7.2	83.8	(30.6-182.5)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	2.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	0.6	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	7	8.4	82.9	(33.2-170.9)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	18	26.9	66.9	(39.6-105.7)
Male	0	0.7	nc	(nc-nc)	Female	16	21.9	72.9	(41.7-118.4)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	3.3	nc	(nc-nc)					
Female	2	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	24.8	100.9	(65.3-149.0)	Male	11	15.5	71.1	(35.4-127.2)
Female	14	10.6	131.7	(71.9-220.9)	Female	7	13.2	53.1	(21.3-109.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.3	116.3	(37.5-271.4)	Male	4	4.2	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	16	13.6	117.6	(67.2-191.0)
Female	78	97.1	80.3	(63.5-100.2)	Female	10	13.3	75.2	(36.0-138.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.3	153.7	(49.5-358.8)	Male	7	9.7	71.9	(28.8-148.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	31	28.4	109.3	(74.2-155.1)	Female	11	9.2	119.9	(59.8-214.6)
Female	24	34.6	69.4	(44.5-103.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	12	8.0	150.0	(77.4-262.1)
Male	6	6.4	93.7	(34.2-203.8)	Female	11	10.6	104.1	(51.9-186.2)
Female	1	2.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	101	91.3	110.7	(90.1-134.5)
Male	3	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	9	5.7	158.4	(72.3-300.7)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	10	4.2	237.0	(113.5-435.8)
Male	11	12.6	87.6	(43.7-156.8)	<b><u>Testis</u></b>				
Female	7	8.4	83.7	(33.5-172.5)	Male	4	2.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	3.7	nc	(nc-nc)	Male	0	4.9	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	15	15.2	98.6	(55.1-162.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	8.9	112.2	(53.7-206.4)	Female	18	22.3	80.7	(47.8-127.6)
Female	10	7.7	130.0	(62.2-239.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	335	323.1	103.7	(92.9-115.4)
Male	7	7.3	96.5	(38.7-198.8)	Female	315	353.9	89.0	(79.5-99.4)
Female	3	2.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	44	44.4	99.2	(72.0-133.1)					
Female	39	53.4	73.0	(51.9-99.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	38	51.7	73.6	(52.0-101.0)	Male	27	38.3	70.6	(46.5-102.7)
Female	21	22.1	95.1	(58.9-145.5)	Female	23	37.9	60.6	(38.4-90.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	12.5	72.2	(33.0-137.1)	Male	9	9.0	99.9	(45.6-189.7)
Female	12	11.5	104.3	(53.8-182.2)	Female	11	8.4	131.0	(65.3-234.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	25	33.4	74.8	(48.4-110.5)
Female	198	233.2	84.9	(73.5-97.6)	Female	23	30.4	75.5	(47.9-113.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	10.9	55.3	(20.2-120.4)	Male	33	23.1	143.1	(98.5-201.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	62	62.3	99.5	(76.3-127.6)	Female	16	22.2	72.2	(41.2-117.3)
Female	74	73.1	101.2	(79.4-127.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	24	16.8	142.6	(91.3-212.1)
Male	13	13.9	93.7	(49.9-160.3)	Female	16	21.8	73.4	(41.9-119.2)
Female	6	4.6	130.5	(47.7-284.1)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	146	196.4	74.3	(62.8-87.4)
Male	15	8.0	187.3	(104.8-308.9)	<b><u>Stomach</u></b>				
Female	3	6.7	nc	(nc-nc)	Male	15	12.4	121.1	(67.7-199.7)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	13	8.9	146.7	(78.0-250.9)
Male	28	29.6	94.6	(62.8-136.7)	<b><u>Testis</u></b>				
Female	17	19.5	87.2	(50.7-139.6)	Male	5	15.9	31.4	(10.1-73.4)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	12	8.1	149.0	(76.9-260.3)	Male	19	15.2	124.9	(75.2-195.1)
Female	3	2.8	nc	(nc-nc)	Female	65	55.8	116.4	(89.8-148.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	20	21.2	94.4	(57.7-145.9)	Female	44	52.3	84.2	(61.2-113.0)
Female	23	18.5	124.5	(78.9-186.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	696	736.4	94.5	(87.6-101.8)
Male	27	16.6	162.3	(106.9-236.2)	Female	760	839.2	90.6	(84.2-97.2)
Female	10	6.3	157.5	(75.4-289.7)					
<b><u>Lung and Bronchus</u></b>									
Male	110	93.7	117.4	(96.5-141.5)					
Female	111	113.9	97.5	(80.2-117.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	23.9	112.8	(74.3-164.1)	Male	22	14.4	152.9	(95.8-231.5)
Female	11	8.4	130.7	(65.1-233.8)	Female	9	11.4	78.6	(35.9-149.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.8	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	0	3.6	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	13	12.7	102.2	(54.4-174.8)
Female	106	79.3	133.6	(109.4-161.6)	Female	9	10.8	83.2	(38.0-158.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.8	nc	(nc-nc)	Male	7	8.7	80.3	(32.2-165.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	33	26.9	122.5	(84.3-172.1)	Female	6	7.6	79.1	(28.9-172.1)
Female	19	27.5	69.0	(41.5-107.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	5.9	nc	(nc-nc)	Male	78	83.7	93.1	(73.6-116.2)
Female	2	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	11.5	95.6	(47.6-171.0)	Female	24	18.2	131.6	(84.3-195.8)
Female	4	6.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	7	3.4	205.2	(82.2-422.7)	Male	8	8.4	95.3	(41.1-187.9)
Female	0	1.0	nc	(nc-nc)	Female	4	6.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	3	6.7	nc	(nc-nc)	Male	46	42.5	108.2	(79.2-144.3)
Female	0	2.4	nc	(nc-nc)	Female	36	42.7	84.4	(59.1-116.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	6.9	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	20	24.9	80.3	(49.1-124.1)	Female	4	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	7.9	63.3	(20.4-147.7)	Female	5	2.2	224.0	(72.2-522.7)
Female	7	6.8	103.0	(41.3-212.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	2.2	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	30	27.1	110.8	(74.7-158.1)
Male	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.8	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	1.9	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.5	nc	(nc-nc)	Female	6	5.8	103.0	(37.6-224.2)
Female	0	1.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	81	94.2	86.0	(68.3-106.9)
Male	2	2.1	nc	(nc-nc)	Female	73	82.1	88.9	(69.7-111.8)
Female	0	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	13.0	46.3	(16.9-100.8)					
Female	9	11.1	81.0	(37.0-153.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	10.0	150.0	(83.9-247.4)	Male	13	6.9	189.0	(100.6-323.3)
Female	1	2.7	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	6	1.8	335.4	(122.5-730.1)
Female	1	1.5	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
Female	39	35.5	109.8	(78.1-150.1)	Female	5	3.9	127.3	(41.0-297.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	7	4.6	152.9	(61.3-315.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	8	12.1	66.0	(28.4-130.1)	Female	3	3.1	nc	(nc-nc)
Female	11	9.2	120.2	(59.9-215.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	3.3	182.3	(66.6-396.7)
Male	2	2.8	nc	(nc-nc)	Female	5	2.7	187.9	(60.5-438.4)
Female	0	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	40	40.8	98.1	(70.1-133.6)
Male	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.1	nc	(nc-nc)
Male	5	5.8	85.7	(27.6-200.1)	<b><u>Testis</u></b>				
Female	0	2.7	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	5	2.4	205.3	(66.2-479.0)
Female	0	0.4	nc	(nc-nc)	Female	3	7.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	7	3.9	180.9	(72.5-372.8)	Female	11	7.9	138.5	(69.0-247.7)
Female	1	2.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	160	141.5	113.1	(96.3-132.1)
Male	3	3.3	nc	(nc-nc)	Female	121	114.6	105.6	(87.6-126.1)
Female	0	0.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	16	18.8	85.3	(48.7-138.5)					
Female	19	14.9	127.2	(76.5-198.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	17.7	124.5	(78.0-188.4)	Male	3	11.5	nc	(nc-nc)
Female	9	7.0	128.5	(58.7-244.0)	Female	2	9.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	8	10.2	78.5	(33.8-154.7)
Female	65	68.9	94.3	(72.8-120.2)	Female	4	9.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.6	nc	(nc-nc)	Male	9	7.3	122.5	(55.9-232.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	27	20.3	132.8	(87.5-193.2)	Female	2	6.5	nc	(nc-nc)
Female	24	23.2	103.5	(66.3-154.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	5.7	157.4	(71.8-298.9)
Male	4	4.7	nc	(nc-nc)	Female	6	7.0	86.3	(31.5-187.8)
Female	1	1.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	50	67.2	74.4	(55.2-98.0)
Male	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	5	4.1	121.4	(39.1-283.4)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	2.8	177.4	(57.2-414.0)
Male	10	9.3	107.1	(51.3-197.0)	<b><u>Testis</u></b>				
Female	10	5.8	173.3	(83.0-318.7)	Male	2	2.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	7	12.7	54.9	(22.0-113.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	7	6.7	104.0	(41.7-214.4)	Female	18	15.6	115.6	(68.5-182.7)
Female	10	5.5	182.5	(87.4-335.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	219	237.8	92.1	(80.3-105.1)
Male	5	5.4	93.1	(30.0-217.4)	Female	222	246.9	89.9	(78.5-102.5)
Female	1	2.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	30	31.7	94.5	(63.7-134.9)					
Female	30	35.1	85.5	(57.7-122.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	10.9	109.8	(56.7-191.8)	Male	2	7.2	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	41	39.2	104.5	(75.0-141.8)	Female	6	4.8	124.6	(45.5-271.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	9	12.6	71.3	(32.5-135.4)	Female	5	3.6	140.3	(45.2-327.3)
Female	18	11.9	150.8	(89.3-238.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	3.5	141.0	(45.4-329.0)
Male	4	2.9	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	43	40.8	105.5	(76.3-142.1)
Male	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.4	nc	(nc-nc)
Male	3	5.9	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	3.2	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	5	7.3	68.9	(22.2-160.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	4.0	nc	(nc-nc)	Female	8	8.9	90.4	(38.9-178.1)
Female	3	2.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	119	146.7	81.1	(67.2-97.1)
Male	2	3.4	nc	(nc-nc)	Female	128	134.3	95.3	(79.5-113.3)
Female	2	1.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	15	19.9	75.3	(42.1-124.3)					
Female	16	18.8	85.3	(48.7-138.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	14.3	126.2	(74.7-199.4)	Male	2	9.6	nc	(nc-nc)
Female	4	4.3	nc	(nc-nc)	Female	2	6.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	7	8.3	84.6	(33.9-174.2)
Female	47	47.9	98.1	(72.1-130.5)	Female	7	5.8	120.2	(48.2-247.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.8	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	15	16.8	89.2	(49.9-147.1)	Female	2	4.4	nc	(nc-nc)
Female	21	14.0	150.2	(92.9-229.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	4.7	105.3	(33.9-245.8)
Male	4	4.1	nc	(nc-nc)	Female	1	4.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	29	61.5	47.1	(31.6-67.7)
Male	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.6	nc	(nc-nc)
Male	9	8.0	112.1	(51.1-212.7)	<b><u>Testis</u></b>				
Female	6	3.9	154.8	(56.5-337.0)	Male	2	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	2.4	210.6	(67.9-491.4)	Male	3	3.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	9.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	5.2	190.6	(91.3-350.6)	Female	12	11.1	108.3	(55.9-189.1)
Female	4	3.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	151	202.4	74.6	(63.2-87.5)
Male	6	4.6	130.3	(47.6-283.5)	Female	154	163.2	94.4	(80.1-110.5)
Female	2	1.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	21	26.9	78.0	(48.3-119.2)					
Female	16	22.9	70.0	(40.0-113.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	91	126.3	72.1	(58.0-88.5)	Male	33	86.1	38.3	(26.4-53.8)
Female	50	51.5	97.0	(72.0-127.9)	Female	42	79.7	52.7	(38.0-71.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	19	27.4	69.3	(41.7-108.2)	Male	22	22.1	99.4	(62.3-150.5)
Female	21	25.9	81.1	(50.2-124.0)	Female	16	19.7	81.1	(46.3-131.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	9	3.9	228.3	(104.2-433.3)	Male	62	76.5	81.0	(62.1-103.9)
Female	497	546.1	91.0	(83.2-99.4)	Female	55	69.6	79.0	(59.5-102.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	33	21.9	150.4	(103.5-211.3)	Male	67	54.8	122.3	(94.8-155.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	149	150.4	99.0	(83.8-116.3)	Female	44	50.7	86.7	(63.0-116.4)
Female	153	169.7	90.2	(76.5-105.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	32	34.1	93.8	(64.1-132.4)	Male	47	41.3	113.9	(83.7-151.5)
Female	10	10.8	92.6	(44.3-170.3)	Female	38	50.8	74.8	(52.9-102.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	16	13.3	120.6	(68.9-195.9)	Male	49	29.9	164.0	(121.3-216.8)
Female	13	12.2	106.7	(56.7-182.4)	Female	23	20.3	113.1	(71.7-169.7)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	81	69.9	115.8	(92.0-143.9)	Male	17	21.9	77.5	(45.1-124.1)
Female	43	45.3	95.0	(68.7-127.9)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	21	19.8	106.2	(65.7-162.3)	Female	112	124.0	90.3	(74.4-108.7)
Female	5	6.6	75.9	(24.5-177.2)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	40	50.7	79.0	(56.4-107.5)	Male	17	30.8	55.3	(32.2-88.5)
Female	38	42.9	88.6	(62.7-121.6)	Female	71	109.5	64.9	(50.6-81.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	53	40.1	132.1	(99.0-172.8)	Female	112	124.0	90.3	(74.4-108.7)
Female	14	15.0	93.0	(50.8-156.1)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	270	230.5	117.1	(103.6-132.0)	Male	1703	1757.1	96.9	(92.4-101.6)
Female	271	267.9	101.2	(89.5-114.0)	Female	1702	1920.1	88.6	(84.5-93.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.8	89.7	(35.9-184.8)	Male	8	5.4	147.4	(63.4-290.4)
Female	5	2.6	193.3	(62.3-451.1)	Female	7	4.3	164.4	(65.9-338.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.8	145.4	(58.2-299.5)
Female	28	31.4	89.2	(59.3-128.9)	Female	4	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	6	3.6	165.4	(60.4-360.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	8	9.5	84.3	(36.3-166.2)	Female	5	2.8	177.8	(57.3-414.9)
Female	11	8.7	126.5	(63.1-226.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	34	31.6	107.6	(74.5-150.3)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	4.6	nc	(nc-nc)	Female	7	7.2	97.7	(39.2-201.4)
Female	5	2.4	206.3	(66.5-481.4)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	9	14.8	61.0	(27.8-115.8)
Female	0	0.8	nc	(nc-nc)	Female	11	13.6	81.0	(40.4-144.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	12	12.8	93.6	(48.3-163.5)	Female	2	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	3.1	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	2	4.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	9	9.4	95.4	(43.5-181.2)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.3	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	6	7.0	85.3	(31.1-185.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	27.8	97.2	(64.0-141.4)	Male	14	17.4	80.4	(43.9-134.9)
Female	9	11.2	80.2	(36.6-152.3)	Female	15	14.6	102.5	(57.3-169.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.9	nc	(nc-nc)	Male	5	4.8	104.8	(33.8-244.5)
Female	4	4.6	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	26	15.4	169.3	(110.6-248.1)
Female	128	106.7	119.9	(100.0-142.6)	Female	10	14.3	70.1	(33.6-129.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	3.7	213.4	(91.9-420.6)	Male	12	10.8	111.5	(57.6-194.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	35	31.9	109.6	(76.3-152.4)	Female	8	10.0	80.2	(34.5-157.9)
Female	38	36.6	103.8	(73.4-142.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	7	7.1	98.7	(39.5-203.4)	Male	93	101.1	92.0	(74.3-112.7)
Female	3	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	4	1.9	nc	(nc-nc)	Male	6	2.9	208.2	(76.0-453.1)
Female	5	1.7	289.6	(93.3-675.9)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	16	14.1	113.7	(64.9-184.6)	Female	28	24.3	115.1	(76.4-166.3)
Female	7	9.1	77.1	(30.9-158.9)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	7	4.1	170.9	(68.5-352.2)	Male	18	10.0	179.3	(106.2-283.4)
Female	2	1.3	nc	(nc-nc)	Female	13	8.3	156.2	(83.1-267.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	9	8.2	110.3	(50.3-209.3)	Male	59	49.9	118.3	(90.0-152.6)
Female	5	3.1	160.3	(51.6-374.0)	Female	53	56.9	93.1	(69.8-121.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	29.3	119.3	(83.1-165.9)	Male	21	19.2	109.1	(67.5-166.8)
Female	14	12.0	116.6	(63.7-195.7)	Female	17	16.9	100.5	(58.5-161.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.6	106.5	(38.9-231.8)	Male	2	5.1	nc	(nc-nc)
Female	7	5.3	133.1	(53.3-274.2)	Female	6	4.6	130.6	(47.7-284.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	21	17.0	123.5	(76.4-188.7)
Female	137	123.8	110.7	(92.9-130.9)	Female	23	15.7	146.1	(92.6-219.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	4.5	199.2	(90.9-378.1)	Male	20	12.4	161.3	(98.5-249.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	42	34.7	120.9	(87.1-163.4)	Female	17	11.4	149.1	(86.8-238.7)
Female	41	39.1	105.0	(75.3-142.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	18	9.6	187.7	(111.2-296.7)
Male	8	7.8	102.4	(44.1-201.8)	Female	8	11.8	67.6	(29.1-133.2)
Female	5	2.5	197.8	(63.8-461.7)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	114	112.1	101.7	(83.9-122.1)
Male	5	2.4	209.9	(67.7-489.9)	<b><u>Stomach</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	7	6.9	101.4	(40.6-209.0)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	9	4.7	192.7	(87.9-365.8)
Male	12	15.8	76.0	(39.2-132.8)	<b><u>Testis</u></b>				
Female	14	10.3	136.2	(74.4-228.5)	Male	1	3.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	8	4.5	177.9	(76.6-350.6)	Male	9	6.6	137.0	(62.5-260.0)
Female	1	1.5	nc	(nc-nc)	Female	39	21.8	179.1	(127.3-244.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	12	11.1	107.8	(55.6-188.2)	Female	19	28.6	66.5	(40.0-103.9)
Female	10	9.1	109.3	(52.3-201.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	439	397.4	110.5	(100.4-121.3)
Male	5	9.0	55.3	(17.8-129.2)	Female	489	432.4	113.1	(103.3-123.6)
Female	3	3.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	63	53.0	118.9	(91.3-152.1)					
Female	68	62.7	108.5	(84.2-137.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	6.3	110.9	(44.4-228.6)	Male	7	4.5	157.1	(62.9-323.6)
Female	3	2.0	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.9	128.3	(41.4-299.5)
Female	34	26.1	130.1	(90.1-181.9)	Female	3	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	7.5	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
Female	7	6.8	103.6	(41.5-213.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	2.1	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	36	27.6	130.3	(91.3-180.4)
Male	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.8	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	5.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	2.5	nc	(nc-nc)	Female	7	6.0	116.3	(46.6-239.7)
Female	0	1.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	87	92.1	94.5	(75.7-116.6)
Male	0	2.2	nc	(nc-nc)	Female	93	84.4	110.2	(89.0-135.1)
Female	2	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	11.9	nc	(nc-nc)					
Female	12	11.2	107.3	(55.4-187.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	7.8	128.1	(61.3-235.6)	Male	6	5.5	108.2	(39.5-235.5)
Female	4	3.4	nc	(nc-nc)	Female	8	5.2	153.8	(66.2-303.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	5	4.8	103.8	(33.4-242.2)
Female	42	38.2	110.1	(79.3-148.8)	Female	3	4.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	15	9.5	158.6	(88.7-261.5)	Female	1	3.5	nc	(nc-nc)
Female	7	11.2	62.4	(25.0-128.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	2.6	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	49	33.5	146.5	(108.3-193.6)
Male	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	1.3	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	7	3.1	226.3	(90.7-466.3)	Male	1	1.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	5	2.0	246.2	(79.3-574.5)
Female	1	0.5	nc	(nc-nc)	Female	5	7.1	70.5	(22.7-164.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	3.0	nc	(nc-nc)	Female	16	8.8	182.4	(104.2-296.2)
Female	3	2.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	128	113.6	112.7	(94.0-134.0)
Male	2	2.7	nc	(nc-nc)	Female	132	129.9	101.6	(85.0-120.5)
Female	1	1.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	11	14.8	74.1	(37.0-132.7)					
Female	16	18.3	87.2	(49.8-141.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	18.9	89.9	(52.3-143.9)	Male	15	12.2	122.7	(68.6-202.4)
Female	7	5.6	125.0	(50.1-257.5)	Female	12	9.1	131.9	(68.1-230.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.7	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	12	11.0	109.4	(56.5-191.1)
Female	92	68.9	133.5	(107.6-163.8)	Female	12	7.8	153.5	(79.2-268.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.7	nc	(nc-nc)	Male	4	7.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	25	22.4	111.7	(72.3-164.9)	Female	4	6.1	nc	(nc-nc)
Female	12	18.7	64.1	(33.1-111.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	2	4.8	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	4	5.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	82	66.3	123.7	(98.4-153.5)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	10	10.1	99.2	(47.5-182.4)	Male	3	4.4	nc	(nc-nc)
Female	2	5.3	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	8	7.2	111.7	(48.1-220.1)	Male	7	4.1	168.8	(67.6-347.8)
Female	7	4.7	148.9	(59.7-306.9)	Female	13	13.1	99.6	(53.0-170.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	5.8	nc	(nc-nc)	Female	12	15.6	77.1	(39.8-134.7)
Female	4	1.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	13	33.7	38.5	(20.5-65.9)	Male	226	248.1	91.1	(79.6-103.8)
Female	27	29.8	90.7	(59.8-132.0)	Female	239	224.9	106.3	(93.2-120.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	12	11.5	104.6	(54.0-182.7)	Female	1	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	4.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	11	11.1	99.4	(49.5-177.8)
Female	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.7	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	5.2	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.4	94.5	(37.9-194.8)	Male	6	5.8	103.0	(37.6-224.3)
Female	4	2.5	nc	(nc-nc)	Female	0	4.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	6	1.5	411.0	(150.1-894.6)
Female	1	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.3	nc	(nc-nc)	Male	11	5.0	221.4	(110.3-396.1)
Female	35	33.1	105.8	(73.7-147.2)	Female	3	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	9.6	72.7	(29.1-149.8)	Female	0	2.9	nc	(nc-nc)
Female	7	8.3	84.0	(33.7-173.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	2.4	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	31	36.7	84.5	(57.4-119.9)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	6	5.1	118.3	(43.2-257.4)	Male	3	1.9	nc	(nc-nc)
Female	5	2.5	198.3	(63.9-462.8)	Female	0	1.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	3	3.1	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	9	6.8	131.8	(60.1-250.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	2.9	nc	(nc-nc)	Female	8	7.5	106.0	(45.6-208.9)
Female	0	0.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	13	14.6	88.8	(47.2-151.8)	Male	115	118.6	97.0	(80.1-116.4)
Female	18	13.7	131.0	(77.6-207.0)	Female	104	106.3	97.8	(79.9-118.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	18.1	105.0	(63.2-164.0)	Male	6	11.1	53.8	(19.7-117.2)
Female	15	7.3	205.9	(115.1-339.6)	Female	12	9.5	125.8	(64.9-219.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.1	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	5	3.0	167.9	(54.1-391.8)	Female	1	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	20	9.9	201.2	(122.8-310.8)
Female	75	70.1	107.0	(84.2-134.1)	Female	13	9.3	140.5	(74.7-240.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.5	nc	(nc-nc)	Male	2	7.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	25	21.0	118.9	(77.0-175.6)	Female	5	6.6	76.2	(24.6-177.9)
Female	24	24.2	99.0	(63.4-147.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	5.8	103.6	(37.8-225.5)
Male	2	4.5	nc	(nc-nc)	Female	5	7.3	68.8	(22.2-160.7)
Female	0	1.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	60	62.5	96.1	(73.3-123.6)
Male	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	3.0	nc	(nc-nc)
Male	9	8.9	100.6	(45.9-191.0)	<b><u>Testis</u></b>				
Female	5	5.8	85.7	(27.6-200.1)	Male	3	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	11	3.5	311.0	(155.0-556.5)
Female	1	0.8	nc	(nc-nc)	Female	11	11.6	95.1	(47.4-170.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	7	6.6	105.8	(42.4-218.0)	Female	23	15.9	145.0	(91.9-217.7)
Female	9	5.5	164.7	(75.2-312.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	232	230.6	100.6	(88.1-114.4)
Male	2	5.2	nc	(nc-nc)	Female	263	250.0	105.2	(92.9-118.7)
Female	0	2.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	32	31.5	101.7	(69.5-143.5)					
Female	31	35.9	86.3	(58.7-122.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	19.9	110.4	(69.2-167.2)	Male	10	13.2	75.7	(36.2-139.2)
Female	10	7.3	137.8	(66.0-253.5)	Female	6	10.2	59.1	(21.6-128.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.7	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	13	11.6	111.8	(59.5-191.3)
Female	63	74.8	84.2	(64.7-107.7)	Female	9	9.5	94.8	(43.3-180.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.7	nc	(nc-nc)	Male	8	8.8	91.1	(39.2-179.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	19	23.5	81.0	(48.7-126.5)	Female	8	6.9	116.2	(50.0-228.9)
Female	20	23.7	84.5	(51.6-130.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	6.5	nc	(nc-nc)
Male	7	5.6	126.1	(50.5-259.8)	Female	8	7.2	111.9	(48.2-220.4)
Female	1	1.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	96	80.2	119.8	(97.0-146.2)
Male	2	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	2.8	nc	(nc-nc)
Male	14	10.9	128.6	(70.2-215.8)	<b><u>Testis</u></b>				
Female	5	6.2	80.9	(26.1-188.9)	Male	3	2.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	7	3.2	219.7	(88.0-452.6)	Male	1	4.5	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	11	13.0	84.4	(42.1-151.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	7.4	67.3	(21.7-157.1)	Female	15	17.3	86.9	(48.6-143.4)
Female	5	5.5	91.5	(29.5-213.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	270	275.0	98.2	(86.8-110.6)
Male	2	6.4	nc	(nc-nc)	Female	231	260.7	88.6	(77.6-100.8)
Female	2	2.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	35	36.3	96.5	(67.2-134.2)					
Female	30	37.7	79.6	(53.7-113.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	48	55.7	86.1	(63.5-114.2)	Male	20	37.5	53.3	(32.6-82.4)
Female	19	21.2	89.5	(53.8-139.7)	Female	25	31.8	78.6	(50.8-116.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	11.3	97.5	(48.6-174.4)	Male	9	9.7	92.4	(42.1-175.4)
Female	10	10.0	100.1	(47.9-184.0)	Female	11	8.1	135.5	(67.5-242.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	5	1.7	288.2	(92.9-672.6)	Male	35	32.7	106.9	(74.5-148.7)
Female	225	222.9	101.0	(88.2-115.0)	Female	39	28.3	137.8	(98.0-188.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	8.8	91.0	(39.2-179.3)	Male	28	23.3	120.1	(79.8-173.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	70	65.2	107.4	(83.7-135.7)	Female	19	20.6	92.2	(55.5-144.0)
Female	90	70.2	128.1	(103.0-157.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	34	18.2	186.7	(129.2-260.8)
Male	19	14.9	127.1	(76.5-198.5)	Female	28	21.0	133.4	(88.6-192.8)
Female	2	4.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	189	217.1	87.1	(75.1-100.4)
Male	8	5.0	160.9	(69.3-317.1)	<b><u>Stomach</u></b>				
Female	9	4.4	205.5	(93.8-390.2)	Male	21	13.0	161.4	(99.9-246.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	8	8.4	94.8	(40.8-186.7)
Male	31	30.6	101.3	(68.8-143.7)	<b><u>Testis</u></b>				
Female	32	18.4	174.2	(119.1-246.0)	Male	9	8.4	107.7	(49.1-204.4)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	11	8.7	126.6	(63.1-226.5)	Male	11	13.0	84.5	(42.1-151.2)
Female	3	2.7	nc	(nc-nc)	Female	57	43.1	132.4	(100.3-171.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	16	21.1	76.0	(43.4-123.4)	Female	39	50.4	77.4	(55.0-105.8)
Female	11	17.0	64.6	(32.2-115.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	801	765.3	104.7	(97.5-112.2)
Male	19	17.3	109.9	(66.1-171.7)	Female	836	780.7	107.1	(99.9-114.6)
Female	6	6.1	97.9	(35.7-213.1)					
<b><u>Lung and Bronchus</u></b>									
Male	133	103.6	128.4	(107.5-152.1)					
Female	125	109.3	114.3	(95.2-136.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	10.1	99.3	(47.5-182.5)	Male	6	6.1	97.8	(35.7-212.8)
Female	2	2.8	nc	(nc-nc)	Female	0	4.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.7	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.6	nc	(nc-nc)
Female	32	30.3	105.5	(72.2-149.0)	Female	3	3.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	11	11.5	96.1	(47.9-171.9)	Female	6	2.8	216.4	(79.0-471.0)
Female	12	9.2	130.4	(67.3-227.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	3.2	nc	(nc-nc)
Male	4	2.4	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	33	32.2	102.6	(70.6-144.0)
Male	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.1	nc	(nc-nc)
Male	6	4.9	122.0	(44.5-265.5)	<b><u>Testis</u></b>				
Female	3	2.5	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	3.6	nc	(nc-nc)	Female	8	6.9	116.3	(50.1-229.3)
Female	1	2.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	110	124.8	88.2	(72.5-106.3)
Male	1	2.7	nc	(nc-nc)	Female	100	104.3	95.9	(78.0-116.6)
Female	0	0.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	16	17.5	91.4	(52.2-148.5)					
Female	19	14.6	130.4	(78.5-203.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	30.2	129.2	(91.9-176.6)	Male	26	20.3	127.9	(83.5-187.4)
Female	14	10.8	129.6	(70.8-217.5)	Female	11	16.6	66.1	(32.9-118.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	5.9	nc	(nc-nc)	Male	7	5.3	131.5	(52.7-271.0)
Female	4	5.2	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	15	17.8	84.3	(47.2-139.1)
Female	106	122.5	86.5	(70.8-104.7)	Female	15	14.7	102.0	(57.1-168.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	4.7	148.6	(59.5-306.2)	Male	13	13.3	97.5	(51.9-166.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	35	36.0	97.2	(67.7-135.2)	Female	16	11.1	144.5	(82.5-234.7)
Female	31	35.2	88.1	(59.9-125.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	17	10.0	170.3	(99.2-272.8)
Male	7	8.3	84.1	(33.7-173.3)	Female	17	10.6	161.0	(93.7-257.8)
Female	3	2.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	128	121.2	105.6	(88.1-125.5)
Male	1	2.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	2	7.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	8	4.1	193.2	(83.2-380.8)
Male	22	16.9	130.5	(81.8-197.7)	<b><u>Testis</u></b>				
Female	8	9.9	81.1	(34.9-159.8)	Male	5	3.9	129.8	(41.8-302.8)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	4.8	124.6	(45.5-271.2)	Male	5	7.0	70.9	(22.9-165.6)
Female	0	1.5	nc	(nc-nc)	Female	31	23.0	134.9	(91.7-191.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	20	11.3	176.4	(107.7-272.4)	Female	32	28.3	113.0	(77.3-159.5)
Female	18	8.6	209.9	(124.3-331.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	449	419.5	107.0	(97.4-117.4)
Male	8	9.7	82.2	(35.4-162.0)	Female	451	413.8	109.0	(99.2-119.5)
Female	1	3.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	53	55.7	95.1	(71.3-124.4)					
Female	70	57.9	120.8	(94.2-152.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	4.5	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	2.7	185.8	(59.9-433.5)
Female	30	19.6	153.2	(103.3-218.7)	Female	1	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.7	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	9	5.3	169.7	(77.5-322.3)	Female	4	1.8	nc	(nc-nc)
Female	12	6.5	183.9	(94.9-321.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	1.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	25	18.8	133.3	(86.2-196.8)
Male	2	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	0.8	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	5	3.3	153.0	(49.3-357.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.7	nc	(nc-nc)	Female	6	4.5	132.1	(48.2-287.5)
Female	0	1.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	81	63.6	127.3	(101.1-158.2)
Male	3	1.5	nc	(nc-nc)	Female	82	69.8	117.6	(93.5-145.9)
Female	1	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	7	8.6	81.8	(32.8-168.5)					
Female	9	10.3	87.1	(39.7-165.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	0	0.0	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	0	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	1	1.6	nc	(nc-nc)	Female	2	11.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	6.4	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	6.6	151.6	(72.6-278.8)	Male	5	4.4	114.6	(36.9-267.4)
Female	3	2.7	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	28	28.5	98.2	(65.2-141.9)	Female	5	3.6	139.6	(45.0-325.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	8.1	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
Female	10	9.1	110.3	(52.8-202.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	45	26.6	169.1	(123.3-226.3)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	3.6	nc	(nc-nc)	Female	8	6.5	123.3	(53.1-242.9)
Female	0	2.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	11	11.9	92.2	(46.0-164.9)
Female	0	0.8	nc	(nc-nc)	Female	16	14.1	113.2	(64.6-183.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	6.8	160.8	(80.2-287.8)	Male	4	5.5	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	5	4.4	112.6	(36.3-262.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.8	104.6	(33.7-244.0)
Female	33	32.3	102.0	(70.2-143.3)	Female	4	3.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	9	9.1	98.9	(45.1-187.7)	Female	5	2.8	176.3	(56.8-411.3)
Female	11	8.2	134.9	(67.2-241.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	2.4	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	22	32.8	67.2	(42.1-101.7)
Male	2	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.9	nc	(nc-nc)
Male	3	4.8	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	2.4	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	5	6.8	73.8	(23.8-172.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	3.0	nc	(nc-nc)	Female	4	7.3	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	101	110.1	91.8	(74.7-111.5)
Male	2	2.7	nc	(nc-nc)	Female	100	103.7	96.4	(78.5-117.3)
Female	2	0.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	16	13.3	120.2	(68.7-195.2)					
Female	13	13.2	98.8	(52.6-169.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	3.8	186.1	(74.6-383.5)	Male	1	2.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	17	11.8	144.1	(83.9-230.7)	Female	1	1.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	4.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	4	1.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	0	0.2	nc	(nc-nc)	Female	8	16.8	47.7	(20.5-93.9)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	1	2.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	1.3	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	0	1.2	nc	(nc-nc)	Male	35	52.5	66.6	(46.4-92.6)
Female	0	0.3	nc	(nc-nc)	Female	38	40.4	94.1	(66.6-129.2)
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	7.2	nc	(nc-nc)	Male	35	52.5	66.6	(46.4-92.6)
Female	4	6.0	nc	(nc-nc)	Female	38	40.4	94.1	(66.6-129.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	7.9	201.3	(115.0-326.9)	Male	6	6.4	93.2	(34.0-202.8)
Female	5	2.9	173.2	(55.8-404.2)	Female	3	5.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.6	nc	(nc-nc)
Female	36	39.0	92.3	(64.6-127.8)	Female	4	4.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	10.9	110.4	(57.0-192.9)	Female	2	3.4	nc	(nc-nc)
Female	6	9.8	61.0	(22.3-132.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	2.8	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	Female	5	2.8	177.6	(57.2-414.4)
Female	2	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	27	38.9	69.4	(45.7-101.0)
Male	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.1	nc	(nc-nc)
Male	3	5.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	3.0	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	11	8.5	130.0	(64.8-232.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.5	nc	(nc-nc)	Female	5	8.7	57.7	(18.6-134.7)
Female	6	2.6	230.5	(84.2-501.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	127	129.3	98.2	(81.9-116.8)
Male	10	3.3	303.3	(145.2-557.8)	Female	127	125.4	101.3	(84.4-120.5)
Female	1	0.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	22	15.4	142.7	(89.4-216.0)					
Female	20	15.8	126.4	(77.2-195.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	5	3.4	146.0	(47.0-340.6)
Male	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	13	10.9	119.3	(63.5-204.1)
Male	0	0.2	nc	(nc-nc)	Female	4	7.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	1.5	nc	(nc-nc)					
Female	0	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.6	106.9	(39.0-232.7)	Male	4	4.2	nc	(nc-nc)
Female	5	2.1	237.2	(76.4-553.5)	Female	3	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.7	135.7	(43.7-316.7)
Female	29	26.1	111.0	(74.3-159.5)	Female	1	3.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	7.3	68.4	(22.0-159.6)	Female	2	2.3	nc	(nc-nc)
Female	4	7.1	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	1.9	nc	(nc-nc)
Male	4	1.6	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	25	24.1	103.8	(67.1-153.2)
Male	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.8	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	8	5.3	150.5	(64.8-296.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	2.3	219.4	(70.7-512.1)	Female	8	5.8	138.2	(59.5-272.2)
Female	2	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	94	83.9	112.0	(90.5-137.1)
Male	4	2.0	nc	(nc-nc)	Female	91	85.9	105.9	(85.3-130.0)
Female	0	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	16	10.7	150.1	(85.7-243.8)					
Female	9	11.3	79.9	(36.4-151.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	12.1	91.0	(45.4-162.8)	Male	7	8.4	82.9	(33.2-170.7)
Female	8	4.2	189.7	(81.7-373.8)	Female	2	6.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	10	7.5	134.1	(64.2-246.7)
Female	47	48.6	96.6	(71.0-128.5)	Female	5	5.8	86.0	(27.7-200.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	6	5.4	110.3	(40.3-240.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	13	14.8	88.0	(46.8-150.5)	Female	3	4.4	nc	(nc-nc)
Female	14	14.0	100.0	(54.6-167.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	4.0	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	Female	5	4.1	120.6	(38.9-281.5)
Female	1	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	63	46.4	135.7	(104.3-173.6)
Male	3	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.7	nc	(nc-nc)
Male	7	6.9	100.9	(40.4-207.9)	<b><u>Testis</u></b>				
Female	5	3.9	128.6	(41.5-300.2)	Male	5	1.9	261.5	(84.3-610.3)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	5	3.1	163.5	(52.7-381.6)
Female	1	0.6	nc	(nc-nc)	Female	7	9.7	72.0	(28.9-148.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	4.7	105.7	(34.1-246.6)	Female	11	10.9	101.1	(50.4-180.8)
Female	5	3.5	142.8	(46.0-333.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	199	168.7	118.0	(102.1-135.5)
Male	2	4.1	nc	(nc-nc)	Female	166	164.3	101.0	(86.2-117.6)
Female	1	1.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	30	22.2	135.4	(91.3-193.3)					
Female	28	22.4	125.1	(83.1-180.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	27.9	118.3	(81.4-166.1)	Male	20	18.2	109.7	(67.0-169.4)
Female	7	10.8	64.8	(25.9-133.4)	Female	19	15.3	124.1	(74.7-193.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.3	94.2	(30.4-219.9)	Male	5	4.8	103.4	(33.3-241.4)
Female	4	4.8	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	15	16.2	92.7	(51.9-152.9)
Female	128	110.6	115.7	(96.6-137.6)	Female	19	14.2	134.3	(80.8-209.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.1	nc	(nc-nc)	Male	11	11.7	94.2	(47.0-168.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	36	33.2	108.5	(76.0-150.2)	Female	6	10.2	58.8	(21.5-128.1)
Female	33	35.7	92.5	(63.6-129.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	9.1	88.3	(38.0-174.0)
Male	7	7.3	95.8	(38.4-197.4)	Female	8	10.7	74.7	(32.2-147.2)
Female	4	2.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	97	103.1	94.1	(76.3-114.8)
Male	2	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	5	6.6	76.2	(24.6-177.9)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	4.3	nc	(nc-nc)
Male	10	14.8	67.5	(32.3-124.1)	<b><u>Testis</u></b>				
Female	7	9.2	76.4	(30.6-157.5)	Male	6	3.5	169.5	(61.9-368.8)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	7	4.2	166.7	(66.8-343.5)	Male	5	6.2	80.4	(25.9-187.5)
Female	2	1.3	nc	(nc-nc)	Female	21	19.9	105.5	(65.3-161.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	10.6	94.6	(45.3-173.9)	Female	20	25.0	80.0	(48.8-123.5)
Female	10	8.4	119.7	(57.3-220.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	366	373.2	98.1	(88.3-108.7)
Male	6	8.5	70.3	(25.7-153.1)	Female	392	388.1	101.0	(91.2-111.5)
Female	3	3.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	47	49.7	94.5	(69.4-125.7)					
Female	52	55.5	93.8	(70.0-123.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	6	7.1	84.0	(30.7-182.8)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	2.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.7	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	4	10.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.2	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	23	33.1	69.5	(44.0-104.3)
Male	1	0.8	nc	(nc-nc)	Female	24	23.0	104.5	(66.9-155.5)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	4	4.3	nc	(nc-nc)					
Female	6	3.0	200.3	(73.1-436.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;